Articles written by Globe Newswire - Benzinga

Melco publishes Company's annual sustainability report "RISE to go Above & Beyond"

MACAU, April 29, 2025 (GLOBE NEWSWIRE) -- Melco Resorts & Entertainment has announced the publication of its sustainability report for the year 2024 (link). The strategy continues to guide the Company to go "Above

XRP News: XenDex Soft Cap Almost Filled as Demand Explodes $XDX Tokens Selling Out Ahead of Exchange Listing

SYDNEY, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- The window is closing fast. XenDex, the revolutionary all-in-one decentralized exchange built on the XRP Ledger, is on the brink of selling out its presale and

MINILUXE REPORTS FULL-YEAR FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 29, 2024

All reported figures in U.S. Dollars unless otherwise noted Boston, MA, April 29, 2025 (GLOBE NEWSWIRE) -- MiniLuxe Holding Corp. (TSXV:MNLX) today announced its financial results for the 52 weeks ended December

AML Go Showcased at MFSA's Virtual Workshop: Mastering FICA Compliance

JOHANNESBURG, April 29, 2025 (GLOBE NEWSWIRE) -- AML Go (Pty) Ltd ("AML Go"), a South African subsidiary of UPAY Inc. (OTCQB:UPYY) and a leading provider of AML compliance and screening solutions, was honored to be

Zapp EV Appoints Authorised Reseller in Ireland

LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ("Zapp EV" or the "Company"), owner of "Zapp", the British electric vehicle brand on a mission to revolutionise personal

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

MIAMI, April 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,

Astec Reports First Quarter 2025 Results, Enters Into Definitive Agreement to Acquire TerraSource Holdings, LLC

First Quarter 2025 Overview (all comparisons are made to the corresponding prior year first quarter unless otherwise specified): Net sales of $329.4 millionStrong net income of $14.3 million; Adjusted net income of

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today

Skye Bioscience to Participate in May Investment and Medical Conferences

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health

Sunrise Padel Capital Closes First Fund and Launches Second to Accelerate Padel Growth Across North America

MIAMI, April 29, 2025 (GLOBE NEWSWIRE) -- Sunrise Padel Capital, a pioneering investment firm focused on scaling padel through strategic real estate and operating investments, today announced the successful closing of

IDV Platform Veriff Accelerates Global Growth with Latin America Expansion

New York, April 29, 2025 (GLOBE NEWSWIRE) -- Veriff, a global AI-native identity verification company powering trust infrastructure online, expands into Latin America with the opening of its Veriff Americas

Inflection Point Acquisition Corp. III Announces Closing of $253,000,000 Million Initial Public Offering

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Inflection Point Acquisition Corp. III (the "Company"), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset

ECARX and Qualcomm Strengthen Relationship to Expand ECARX Product Portfolio Based on Snapdragon Cockpit Platforms

SHANGHAI, April 29, 2025 (GLOBE NEWSWIRE) -- ECARX (NASDAQ:ECX), ("ECARX" or the "Company"), a global automotive technology provider, announced a new phase of its collaboration with Qualcomm Technologies, Inc. Building

OTC Markets Group Welcomes BW Energy Limited to OTCQX

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced BW Energy Limited (Oslo Bors: BWE,

CECO Environmental Reports First Quarter 2025 Results

Numerous Financial Records Reflect Strength of Well-Positioned PortfolioCompany Maintains Full Year Outlook ADDISON, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (NASDAQ:CECO) ("CECO"),

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025

RTOERO honours a lifetime champion for seniors: Susan Walsh receives the Award for Eminent Contribution

Toronto, Ontario, April 29, 2025 (GLOBE NEWSWIRE) -- Susan Walsh of Newfoundland has been named the second ever recipient of the RTOERO Award for Eminent Contribution to Seniors in Canada. Her career has taken her from

EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting

Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025. Study achieved its primary endpoint and

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report